Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVO

Novo Nordisk ADR

Apr 30 • 11:25AM ET

42.50

+2.21 5.48 %

Healthcare • Drug Manufacturers - General • Denmark • Large • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN-D PFE SNY BMY GSK

| Held by: PVAL PPH AVDE PID WCMI PINK AQEC OZEM APIE NVOH

Scroll to Statements

Index	-	P/E	12.25	EPS (ttm)	3.47	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	10.33%
Market Cap	143.18B	Forward P/E	12.87	EPS next Y	3.30	Insider Trans	-	Shs Float	3.37B	Perf Month	15.64%
Enterprise Value	159.53B	PEG	-	EPS next Q	0.88	Inst Own	9.29%	Short Float	0.51%	Perf Quarter	-28.37%
Income	15.45B	P/S	3.06	EPS this Y	-9.55%	Inst Trans	-0.15%	Short Ratio	0.77	Perf Half Y	-18.35%
Sales	46.77B	P/B	6.19	EPS next Y	0.31%	ROA	20.59%	Short Interest	17.02M	Perf YTD	-16.47%
Book/sh	6.87	P/C	33.77	EPS next 5Y	-0.47%	ROE	61.25%	52W High	81.44 -47.82%	Perf Year	-36.04%
Cash/sh	1.26	P/FCF	16.00	EPS past 3/5Y	26.28% 20.36%	ROIC	31.38%	52W Low	35.12 21.01%	Perf 3Y	-49.13%
Dividend Est.	1.72 (4.04%)	EV/EBITDA	7.06	Sales past 3/5Y	23.19% 19.21%	Gross Margin	80.90%	Volatility	2.86% 2.75%	Perf 5Y	14.94%
Dividend TTM	1.80 (4.24%)	EV/Sales	3.41	EPS Y/Y TTM	5.57%	Oper. Margin	41.17%	ATR (14)	1.35	Perf 10Y	52.35%
Dividend Ex-Date	Mar 30, 2026	Quick Ratio	0.57	Sales Y/Y TTM	11.11%	Profit Margin	33.03%	RSI (14)	63.79	Recom	2.50
Dividend Gr. 3/5Y	26.98% 19.93%	Current Ratio	0.80	EPS Q/Q	3.95%	SMA20	8.06%	Beta	0.74	Target Price	48.38
Payout	36.87%	Debt/Eq	0.67	Sales Q/Q	0.66%	SMA50	9.71%	Rel Volume	1.88	Prev Close	40.29
Employees	68794	LT Debt/Eq	0.61	Earnings	Feb 04 BMO	SMA200	-15.33%	Avg Volume	22.01M	Price	42.50
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.40% 3.10%	Trades		Volume	13,678,356	Change	5.48%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Today 11:06AM	Qualcomm stock surges on data center demand, Eli Lilly lifts outlook (Yahoo Finance Video) +5.48%
06:58AM	Lilly's stock rallies as sales of GLP-1 drugs nearly double (MarketWatch)
Apr-29-26 03:19PM	Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug (GuruFocus.com)
03:11PM	Meta is heading into earnings with a big move expected (GuruFocus.com)
Apr-28-26 12:29PM	Erasca Stock Sinks 50% in Race for 'Miracle' Cancer Drug. What's Behind the Historic Sell-Off. (Barrons.com)
07:44AM	Loading…
07:44AM	Boehringer dual-acting obesity shot hits mark in Phase 3 trial (BioPharma Dive)
Apr-27-26 10:02AM	GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival (Proactive)
09:48AM	As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst (Barrons.com)
Apr-24-26 01:53PM	Eli Lilly Stock Falls. Novo Extends Lead in Weight-Loss Drug Race (GuruFocus.com) +6.88%
01:12PM	Eli Lilly Slips as Obesity Prescriptions Lag (GuruFocus.com)
11:46AM	Eli Lilly Stock Falls. Foundayo Is Fighting to Catch Novo's Wegovy Pill. (Barrons.com)
11:00AM	Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims (Yahoo Finance Video)
09:44AM	Intel upgraded, DraftKings downgraded: Wall Street's top analyst calls (The Fly)
06:46AM	Lilly tumbles on Foundayos shaky week; FDA to issue vouchers for psychedelics (BioPharma Dive)
Apr-23-26 02:41PM	Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the 'Netflix' Argument Is Failing. (Barrons.com)
12:47PM	Loading…
12:47PM	This Pharma Stock Is Soaring After Earnings. It's a Sneaky GLP-1 Play. (Barrons.com)
11:53AM	Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma? (Barrons.com)
11:01AM	Novo Nordisk Advances Ozempic Pill for Kids (GuruFocus.com)
10:44AM	Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma. (Barrons.com)
10:06AM	Hims & Hers jumps 7% after expanding partnership with Eli Lilly (InvestorsHub)
Apr-21-26 04:25PM	Amazon launching weight loss drug program via One Medical (Quartz)
01:54PM	Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50 (MarketWatch)
01:30PM	Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game. (Barrons.com)
Apr-20-26 10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
10:33AM	Beyond GLP-1Rs: emerging targets poised to gain share of obesity market (Pharmaceutical Technology)
10:16AM	Agios Pharmaceuticals stock tumbles 25% after Novo data (Investing.com)
Apr-17-26 10:02AM	Eli Lilly Weight-Loss Pill Prescriptions Near 1,400 in First Week (GuruFocus.com)
06:04AM	Lillys obesity pill off to a strong start; OpenAI debuts new drug discovery tool (BioPharma Dive)
Apr-16-26 04:38PM	Kailera nets $625M in one of biotechs biggest-ever IPOs (BioPharma Dive)
03:57PM	Novo Workforce Changes May Signal Ongoing Reset (GuruFocus.com)
01:13PM	Loading…
01:13PM	Novo Nordisk Expands Workforce After Deep Cuts (GuruFocus.com)
10:45AM	Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides (Yahoo Finance)
10:45AM	Hims & Hers stock extends gains as FDA considers looser restrictions on peptides (Yahoo Finance)
Apr-15-26 04:05PM	Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown? (Barrons.com)
06:56AM	Novo Resources appoints GM of exploration ahead of Wyloo drilling (Proactive)
05:39AM	FDA asks Lilly to evaluate obesity pills liver risk (BioPharma Dive)
Apr-14-26 08:12PM	Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval? (Quartz)
03:14PM	Novo Nordisk CEO: This is where science meets speed and scale (CNBC TV)
11:56AM	Novo Bets on OpenAI to Rebuild Its Obesity Edge (GuruFocus.com)
11:54AM	Wall Street Resets Novo Nordisk Price Target (GuruFocus.com)
11:52AM	Novo Nordisk Is Bringing AI Into The Core Of Its Business (GuruFocus.com)
09:11AM	Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI (MarketWatch)
08:58AM	Novo Nordisk Taps OpenAI to Accelerate Drug Development (GuruFocus.com)
07:27AM	Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic. (Barrons.com)
07:24AM	Novo Nordisk partners with OpenAI to speed weight loss drug discovery (Quartz)
07:00AM	Novo Nordisk and OpenAI forge alliance to drive speedy drug development (Pharmaceutical Technology)
06:05AM	These Stocks Are Today's Movers: Intel, American, Oracle, Novo Nordisk, Bloom Energy, Globalstar, JPMorgan, and More (Barrons.com)
04:30AM	GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates (Proactive)
02:04AM	Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development (Reuters)
Apr-13-26 11:43AM	How Eli Lilly Stock Rises To $2,000 (Trefis)
Apr-11-26 06:00AM	Wyloo project drilling to drive Novo news flow - ICYMI (Proactive)
Apr-10-26 12:08PM	Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank (Proactive)
09:26AM	Why Is HIMS Stock Down 40%? (Trefis)
09:03AM	Eli Lilly loses weight loss drug market share as generics flood India (Quartz)
Apr-09-26 03:30PM	Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment (CNBC TV)
01:27PM	Eli Lilly's Foundayo Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock. (Barrons.com)
01:25PM	CRWV, CVX, LLY, TSLA Lead Thursday Watchlist (GuruFocus.com)
01:23PM	Eli Lilly Stock in Focus -- New Pill Launch Challenges Novo Nordisk (GuruFocus.com)
01:20PM	Amazon Push Into GLP-1 Access Expands Healthcare Reach (GuruFocus.com)
11:14AM	Semaglutide Generics Drive 33% Share As India GLP-1 Market Shifts (GuruFocus.com)
Apr-08-26 04:42PM	Novo-Backed Respiratory Drugmaker Avalyn Pharma Files for US IPO (Bloomberg)
06:15AM	A high dose of Wegovy will cost $50 less than Zepbound (MarketWatch)
05:37AM	Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs expected study failure (BioPharma Dive)
Apr-07-26 08:23PM	Novo to kick off 2026 with maiden Wyloo drill campaign (Proactive)
05:47PM	The $190 Billion 'Diabesity' Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts. (Barrons.com)
02:14PM	Novo Nordisk Unveils $399 Wegovy HD, Undercutting Lilly By About 40% (GuruFocus.com)
10:39AM	Ulta Beauty CEO: GLP-1 effects on hair, skin could boost demand for beauty products (Yahoo Finance)
Apr-06-26 02:45PM	Novo Nordisk says Wegovy shows greater weight loss than Eli Lilly's rival pill (Quartz)
11:21AM	Novo Says Weight-Loss Boom Is Just Beginning (GuruFocus.com)
Apr-02-26 04:05PM	Trump slaps steep tariffs on patented drug imports (Supply Chain Dive)
03:26PM	Novo Nordisk Releases Data Showing 3.2% Greater Weight Loss vs Lilly Pill (GuruFocus.com)
10:13AM	Novo: Wegovy produces greater weight loss than Eli Lilly's new pill (Quartz)
10:13AM	Novo Nordisk says Wegovy beats Eli Lilly's pill on weight loss (Quartz)
08:15AM	GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure (Proactive)
07:31AM	Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry (Pharmaceutical Technology)
Apr-01-26 05:33PM	Eli Lilly May Have Found Its Edge In Weight Loss Race (GuruFocus.com)
05:07PM	Novo's New US Chief on Lilly's Rival Weight-Loss Pill (Bloomberg)
02:52PM	Lilly Wins FDA Approval for Oral GLP-1 Weight-Loss Pill (GuruFocus.com)
02:31PM	Eli Lilly stock pops after FDA approves new GLP-1 weight-loss pill (Yahoo Finance)
02:31PM	Lillys Obesity Pill Gets US Approval in Challenge to Novo (Bloomberg)
02:23PM	Eli Lilly wins approval for new weight-loss pill. What to know. (USA TODAY)
01:39PM	SpaceX files confidential IPO, Eli Lilly's obesity pill gets US approval (Yahoo Finance Video)
12:32PM	America has a new weight-loss drug, and it's a pill (MarketWatch)
11:50AM	Eli Lilly Stock Jumps. A Weight-Loss Pill Is Officially on the Market. (Barrons.com)
09:46AM	Disney upgraded, Nike downgraded: Wall Street's top analyst calls (The Fly)
08:30AM	Omeros Corporation Q4 2025 Earnings Call Summary (Moby)
Mar-31-26 11:02PM	Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ... (GuruFocus.com)
05:23PM	Novo launches $249 Wegovy subscription, undercutting Lilly as shares fall 30% (GuruFocus.com)
09:15AM	Novo Nordisk launches Wegovy subscription program (Quartz)
09:15AM	Novo Nordisk launches a new Wegovy subscription as it trails Eli Lilly in the weight loss drug race (Quartz)
Mar-30-26 11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
10:44AM	Pharma Stocks Pfizer, GSK Offer Defensive Plays in an Uncertain Market: Charts (Barrons.com)
10:23AM	Mars CEO gets board role at GLP-1 supplier Novo Nordisk (Just Food)
06:10AM	Novo Nordisk receives FDA approval for basal insulin Awiqli (Pharmaceutical Business Review)
06:00AM	Stocks, sectors, and charts this strategist is watching (Yahoo Finance Video)
Mar-27-26 04:00AM	Novos FDA voucher victory; biotechs rigid glass ceiling (Pharma Voice)
Mar-26-26 09:40AM	Wave Plunges More Than 50% After Obesity Shot Falls Short (Bloomberg)
08:30AM	Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause (Proactive)
Mar-24-26 12:15PM	Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter (Proactive)
Mar-23-26 03:28PM	India Opened the Floodgates on Weight-Loss Generics (Moby)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your Finviz experience